Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,743 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cardiovascular Risks Clear all

Conditions: Multiple Myeloma
Interventions: bb2121, Lenalomide, Talquetamab; Biological · Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 18
States / cities: Scottsdale, Arizona • San Francisco, California • Tampa, Florida + 12 more

Conditions: Obesity, Overweight
Interventions: Tirzepatide, Semaglutide; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 100,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-Alcoholic Fatty Liver Disease, Obesity, Obesity, Abdominal, Liver Fat, Fatty Liver
Interventions: Tesamorelin, Identical Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atherosclerosis, Cardiovascular Diseases
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 20 Years to 85 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Carotid Stenosis
Interventions: Carotid Stent Implantation, Embolic Protection; Device
Lead sponsor: Kensey Nash Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 31
States / cities: Birmingham, Alabama • Fairhope, Alabama • Beverly Hills, California + 25 more

Conditions: Hereditary Hemorrhagic Telangiectasia
Interventions: Not listed
Lead sponsor: Unity Health Toronto; Other
Eligibility: Not listed
Enrollment: 2,272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2025
U.S. locations: 14
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 11 more

Conditions: Type2diabetes, Heart Failure, Obesity
Interventions: Community Champions, Homegrown Heroes; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 30 Years to 70 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Baltimore, Maryland • Hagerstown, Maryland

Conditions: Hypertriglyceridemia
Interventions: Docosahexenoic acid (DHA), Olive oil; Dietary Supplement
Lead sponsor: USDA, Western Human Nutrition Research Center; Federal
Eligibility: 39 Years to 66 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Davis, California

Conditions: Coronary Disease, Cardiovascular Diseases
Interventions: Heart to Heart (Web-Based Decision Aid), Physician Education Session; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 40 Years to 79 Years
Enrollment: 186 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Chapel Hill, North Carolina

Conditions: Type 2 Diabetes Mellitus
Interventions: Efpeglenatide (SAR439977), Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 4,076 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 79
States / cities: Sheffield, Alabama • Gilbert, Arizona • Surprise, Arizona + 69 more

Conditions: Cardiovascular Disease With Mention of Arteriosclerosis, Elevated Cholesterol, Familial Hypercholesterolemia
Interventions: lerodalcibep; Drug
Lead sponsor: LIB Therapeutics LLC; Industry
Eligibility: 10 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: Evanston, Illinois • Cincinnati, Ohio

Conditions: Prostate Cancer, Multiple Myeloma, Smoldering Multiple Myeloma (SMM), Monoclonal Gammopathy of Undetermined Significance
Interventions: Curcumin plus Piperine; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Sudden Cardiac Death
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Peripheral Arterial Disease
Interventions: VibratoSleeve Therapeutic Ultrasound Device; Device
Lead sponsor: Vibrato Medical, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Orange, California

Conditions: Coronary Heart Disease
Interventions: montelukast, Placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Cardiovascular Disease
Interventions: Walnut "meat", Walnut Oil, Walnut Skins, Whole walnut; Dietary Supplement
Lead sponsor: Penn State University; Other
Eligibility: 21 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Acute Leukemia, Chronic Leukemia, Myelodysplastic Syndrome, Lymphomas, Multiple Myeloma
Interventions: MLN9708; Drug
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hypertension, Elevated Cholesterol, Overweight and Obesity
Interventions: Dietary Intervention; Other
Lead sponsor: Texas Woman's University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Atrial Fibrillation, Stroke
Interventions: Apixaban, aspirin; Drug
Lead sponsor: Population Health Research Institute; Other
Eligibility: 55 Years and older
Enrollment: 4,012 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 23
States / cities: Mesa, Arizona • Little Rock, Arkansas • Larkspur, California + 20 more

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • Chapel Hill, North Carolina • High Point, North Carolina + 4 more

Conditions: Cardiovascular Diseases, Cardiovascular Risk Factor, Nutrition Disorders, Diabetes, Hypertension, Cancer, Depression, Obesity, Physical Activity
Interventions: Treatment; Behavioral
Lead sponsor: Tulane University; Other
Eligibility: 7 Years to 115 Years
Enrollment: 7,192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, FDG-Positron Emission Tomography, Pomalidomide, Teclistamab; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 32
States / cities: Coeur d'Alene, Idaho • Post Falls, Idaho • Sandpoint, Idaho + 23 more

Conditions: Metabolic Syndrome, Cardiovascular Disease
Interventions: BOLD Diet, BOLD-X Diet, Modified DASH Diet; Dietary Supplement
Lead sponsor: Penn State University; Other
Eligibility: 30 Years to 60 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Cardiovascular Diseases, Diabetes Mellitus, Obesity
Interventions: Personal testimonial, Forks Over Knives Documentary, Commitment nudge, Prevention nudge; Behavioral
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years and older
Enrollment: 11,234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Danville, Pennsylvania

Search by objective public record fields.

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma

Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes.

Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk

Using Differences in Peripheral Blood Leukocyte Gene Expression to Determine Cardiovascular Disease Risk

Evaluation of the TriActiv ProGuard System During Carotid Artery Stenting

Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia

Understanding and Addressing Risks of Low Socioeconomic Status and Diabetes for Heart Failure

Docosahexenoic Acid (DHA) Supplementation and Cardiovascular Disease in Men With High Triglycerides

Evaluating a Web-Based Educational Program for Adults at Risk for Coronary Heart Disease (The Heart to Heart Feasibility Study)

Effect of Efpeglenatide on Cardiovascular Outcomes

Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction

Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer

Imaging Techniques for Identifying Factors of Sudden Cardiac Death Risk

Feasibility Study to Evaluate Therapeutic Ultrasound (TUS) to Acutely Increase the Perfusion in Peripheral Arterial Disease (PAD)

Study of the Arachidonate 5-Lipoxygenase Enzyme in Affecting the Risk for Coronary Heart Disease

Postprandial Effects of Walnut Components Versus Whole Walnuts on Cardiovascular Disease (CVD) Risk Reduction

Nonmyeloablative Haploidentical Transplant Followed by MLN9708

Effects of a 4-week Raw, Plant-based Diet on Anthropometric and Cardiovascular Risk Factors

Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

Cardiovascular Risk and Preventive Care in Prostate Cancer Patients Receiving Radiation and Hormone Therapy

Cooking for Health Optimization With Patients

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

Beef in an Optimal Lean Diet (BOLD) Effects on Metabolic Syndrome

Evaluation of a Letter Intervention Promoting a Plant-based Diet